The effect of rifampin on the pharmacokinetics of sirolimus in healthy volunteers.

Tortorici, Michael A; Matschke, Kyle; Korth-Bradley, Joan M; DiLea, Cliff; Lasseter, Kenneth C

Tortorici, Michael A; Matschke, Kyle; Korth-Bradley, Joan M; DiLea, Cliff; Lasseter, Kenneth C.

Afiliación

Tortorici MA; Associate Director, Clinical Pharmacology, Specialty Care Business Unit, Pfizer Inc, Collegeville, PA, USA.
Matschke K; Pharmacometrician, Statistics, Primary Care Business Unit, Pfizer Inc, Collegeville, PA, USA.
Korth-Bradley JM; Senior Director, Clinical Pharmacology, Specialty Care Business Unit, Pfizer Inc, Collegeville, PA, USA.
DiLea C; Wyeth Research, Collegeville, PA, USA.
Lasseter KC; Clinical Pharmacology of Miami, Miami, FL, USA.

Clin Pharmacol Drug Dev ; 3(1): 51-6, 2014 Jan.

Article en En | MEDLINE | ID: mdl-27128230

Palabras clave

drug interaction; healthy volunteers; rifampin; sirolimus

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Clin Pharmacol Drug Dev Año: 2014 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Estados Unidos

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google